← Leaderboards
Jason Matthew Elinoff
Clinical Center
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Clinical Center
Same institution · by research overlap
Others in their field
Top investigators on “Pulmonary Arterial Hypertension”
- Marlene Rabinovitch · Stanford University$37,720,523
- Steven M Kawut · Columbia University Health Sciences$25,762,724
- Jason X.-J. Yuan · University Of California, San Diego$23,310,307
- Mark Thomas Gladwin · Clinical Center$17,771,315
- William C Nichols · Children'S Hospital Med Ctr (Cincinnati)$16,040,000
- Vasan S. Ramachandran · Boston University Medical Campus$14,020,252
Research focus
Pulmonary Arterial HypertensionPulmonary Artery StructureCessation Of LifeIn VitroSignal TransductionLungPulmonary HypertensionInhibitor/AntagonistBlood VesselsCellsRattusAnimal ModelInflammationHeart FailureHypoxiaDistalInflammatoryPulmonary Artery Endothelial CellHeartSu 5416United States National Institutes Of HealthDiagnosisExposure ToCardiac
Grant awards (19)
Cellular and Molecular Consequences of SARS-CoV2 Infection in Pulmonary Vascular Endothelium$0
ZIA · FY2022 · CL · contact PI
A Phase 1 Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients with Severe Pulmonary Arterial Hypertension (PAH)$0
ZIA · FY2022 · CL · contact PI
The Effects of Spironolactone on Inflammation in a Rodent Model of Pulmonary Arterial Hypertension$0
ZIA · FY2022 · CL · contact PI
Cellular Models of PAH-Associated Molecular Defects as a Tool for Identifying New Therapeutic Targets$0
ZIA · FY2022 · CL · contact PI
Cellular and Molecular Consequences of SARS-CoV2 Infection in Pulmonary Vascular Endothelium$0
ZIA · FY2021 · CL · contact PI
A Phase 1 Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients with Severe Pulmonary Arterial Hypertension (PAH)$0
ZIA · FY2021 · CL · contact PI
Cellular Models of PAH-Associated Molecular Defects as a Tool for Identifying New Therapeutic Targets$0
ZIA · FY2021 · CL · contact PI
The Effects of Spironolactone on Inflammation in a Rodent Model of Pulmonary Arterial Hypertension$0
ZIA · FY2021 · CL · contact PI
Cellular Models of PAH-Associated Molecular Defects as a Tool for Identifying New Therapeutic Targets$0
ZIA · FY2020 · CL · contact PI
The Effects of Spironolactone on Inflammation in a Rodent Model of Pulmonary Arterial Hypertension$0
ZIA · FY2020 · CL · contact PI
A Phase 1 Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients with Severe Pulmonary Arterial Hypertension (PAH)$0
ZIA · FY2020 · CL · contact PI
Cellular and Molecular Consequences of SARS-VoV2 Infection in Pulmonary Vscular Endothelium$0
ZIA · FY2020 · CL · contact PI
The Effects of Spironolactone on Inflammation in a Rodent Model of Pulmonary Arterial Hypertension$0
ZIA · FY2019 · CL · contact PI
Development of a Pre-Clinical Rodent Model of Pulmonary Arterial Hypertension$0
ZIA · FY2019 · CL · contact PI
A Phase 1 Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients with Severe Pulmonary Arterial Hypertension (PAH)$0
ZIA · FY2019 · CL · contact PI
A Phase 1 Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients with Severe Pulmonary Arterial Hypertension (PAH)$0
ZIA · FY2018 · CL · contact PI
The Effects of Spironolactone on Inflammation in a Rodent Model of Pulmonary Arterial Hypertension$0
ZIA · FY2018 · CL · contact PI
The Effects of Spironolactone on Inflammation in a Rodent Model of Pulmonary Arterial Hypertension$0
ZIA · FY2017 · CL · contact PI
The Effects of Spironolactone on Inflammation in a Rodent Model of Pulmonary Arterial Hypertension$0
ZIA · FY2016 · CL · contact PI